Skip to main content

Alnylam shares hit all-time high as rare disease drug continues to impress

The Cambridge company unveiled late-stage trial data indicating that the drug is more effective that one being developed by a competitor.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.